Search Results
Jan 06, 2026, 08:00 ET Chromatin Bioscience, Mediphage Bioceuticals, and Entos Pharmaceuticals, collaborate on Genetic Medicines Project with support from UKRI Innovate UK and Canadian R&D Funding
focused on the design and development of synthetic promoters for targeted eukaryotic gene control systems. Its proprietary platform, chromatinLENS TM, enables precise, cell-type-selective, and durable gene expression, which is key to advancing the next generation of genetic medicines. Chromatin's
More news about: CHROMATIN BIOSCIENCE LTD
Jan 06, 2026, 08:00 ET Unchained Labs Cracks the Code on ADC Characterization
Calif., Jan. 6, 2026 /PRNewswire/ -- Unchained Labs, the life sciences company that's all about getting biologics and gene therapy researchers the right tool for the job, just launched a brand-new application on Stunner today that delivers rapid, low-volume antibody-drug
More news about: Unchained Labs
Jan 06, 2026, 08:00 ET Unchained Labs Cracks the Code on ADC Characterization
Calif., Jan. 6, 2026 /PRNewswire/ -- Unchained Labs, the life sciences company that's all about getting biologics and gene therapy researchers the right tool for the job, just launched a brand-new application on Stunner today that delivers rapid, low-volume antibody-drug
More news about: Unchained Labs
Jan 06, 2026, 07:17 ET Federal Appeals Court Sides With Natural Grocers® in GMO Labeling Case
in 2014. The company prohibits most GMO ingredients in the grocery products it sells, including those produced using new genetic techniques such as gene-editing and cell culture.Natural Grocers' philosophy is simple: food should come from real sources and undergo as few modifications as possible.
More news about: Natural Grocers by Vitamin Cottage, Inc.
Jan 06, 2026, 07:03 ET Variant Bio Launches Inference, the World's First Agentic AI Genomic Drug Discovery Platform
available for dynamic downstream analyses. A proprietary application programming interface (API) powers the entire platform, enabling instant retrieval of gene and variant-level data across hundreds of millions of data points in seconds."With Inference, we built the tool we wished existed
More news about: Variant Bio
Jan 06, 2026, 07:00 ET Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies
(NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced preliminary in vivo preclinical proof-of-concept data for GPX-002, the Company's diabetes gene therapy drug candidate which may have the
More news about: Genprex, Inc.
Jan 05, 2026, 21:08 ET The Inner Circle acknowledges, Sinisa Dovat, MD, Ph.D. as a Pinnacle Lifetime Member
Pediatric Experimental Therapeutics Program. He plays a pivotal role in the Four Diamonds Pediatric Cancer Research Center, leading research on the Ikaros gene and its implications in high-risk childhood leukemia. Dr. Dovat's work includes developing novel drug designs and targeted therapies to combat pediatric
More news about: The Inner Circle
Jan 05, 2026, 17:31 ET Castration-sensitive Prostate Cancer Market Projected to Grow at a 13.2% CAGR (2020-2034), Driven by Expanded Approval and Wider Commercialization Opportunity in nmCSPC Segment | DelveInsight
TherapiesThe development of therapies targeting specific mutations is expected to perform better in the future, such as AKEEGA (HRR gene-mutated mCSPC), TALZENNA (DDR-deficient mCSPC), TRUQAP (de novo PTEN-deficient mHSPC), and others.Radioligand and PARP Inhibitors
More news about: DelveInsight Business Research, LLP
Jan 05, 2026, 11:15 ET GenEditBio Receives FDA Clearance of IND Application for Its Lead In Vivo Genome-Editing Program GEB-101 for TGFBI Corneal Dystrophy
GenEditBio.About TGFBI Corneal DystrophyTGFBI corneal dystrophy is a group of genetic eye disorders caused by mutations in the TGFBI gene, resulting in progressive abnormal protein buildup and deposits in the cornea. Symptoms include photophobia, gradual vision loss and recurrent corneal
More news about: GenEditBio Limited
Jan 05, 2026, 10:30 ET Cell Culture Vessels Market worth $8.03 billion by 2030 | MarketsandMarkets™
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=75000041 The cell culture vessels market is growing rapidly, driven by advancements in biologics, vaccines, and cell and gene therapies, which require efficient and scalable cell expansion platforms. The use of advanced cell culture methods for drug discovery and toxicity testing
More news about: MarketsandMarkets
Jan 05, 2026, 09:30 ET Mira Precision Health, Based in Mason, Ohio, Announces U.S. Launch of ToxNav® Advantage™ at the 2026 ASCO® GI Cancers Symposium
treatment with fluoropyrimidines.Key features of ToxNav® Advantage™ include:Comprehensive analysis of 23 DPYD gene variantsInclusion of DGLUCY and ENOSF1/TYMS variants predictive of fluoropyrimidine-associated cardiotoxicity (CTRCD) and Hand-Foot Syndrome
More news about: City of Mason
Jan 05, 2026, 09:00 ET Morrison Foerster Elects 17 Partners
and biotechnology sectors. She has significant experience representing leading innovators in matters involving biologics, antibody-drug conjugates, gene therapy, and bio-manufacturing technologies. Sumaiya has litigated across multiple forums, including federal district courts, the Patent Trial and Appeal
More news about: Morrison Foerster
Jan 05, 2026, 08:00 ET Kenai Therapeutics Receives $8M Grant from California Institute for Regenerative Medicine (CIRM) to Advance RNDP-001 for Treatment of Idiopathic Parkinson's Disease
California to fund stem cell and gene therapy research with the goal of accelerating treatments for patients with unmet medical needs. With $8.5 billion in funding allocated through both Proposition 71 in 2004 and Proposition 14 in 2020, CIRM supports stem cell and gene therapy discoveries from inception
More news about: Kenai Therapeutics/BIOCOM
Jan 05, 2026, 03:15 ET GenEditBio Receives FDA Clearance of IND Application for Its Lead In Vivo Genome-Editing Program GEB-101 for TGFBI Corneal Dystrophy
TGFBI gene. GEB-101 is encapsulated as ribonucleoprotein in engineered protein delivery vehicle (PDV), a proprietary in vivo delivery system developed by GenEditBio.About GenEditBioEstablished in 2021 and headquartered in Hong Kong, China, GenEditBio is a clinical-stage gene therapy
More news about: GenEditBio Limited
Jan 02, 2026, 13:29 ET Gene Therapy: 5 Biotech Stocks Chasing the $36B Prize
Equity Insider News Commentary – The gene therapy market is surging toward $36.55 billion by 2032, powered by rising demand for curative treatments that target genetic diseases at their source[1].
More news about: Equity Insider
Jan 02, 2026, 07:00 ET Insmed To Present at the 44th Annual J.P. Morgan Healthcare Conference
therapies to treat chronic, debilitating lung diseases. The Company's early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.Headquartered in Bridgewater, New Jersey,
More news about: Insmed Incorporated
Jan 02, 2026, 01:00 ET Ecovyst Completes Sale of Advanced Materials & Catalysts Segment to Technip Energies
EBITDA from continuing operations of approximately $170 million provided in November 3, 2025 earnings release.For more information:Gene Shiels – Director of Investor Relations(484) 617 [email protected]
More news about: Ecovyst Inc.
Jan 01, 2026, 09:30 ET Columbus Marathon Set Fundraising Record for Nationwide Children's Hospital in 2025
Cell Ovarian Tumor, Pataskala, OHDon, 7, Spastic Quad Cerebral Palsy and Hereditary Spastic Paraplegia Type 4, Zanesville, OHFinn, 9, Gene Deletion, Adrenal Insufficiency and Hypothyroidism, Springfield, OHKaden, 9, SC Sickle Cell, Cystic Fibrosis, and Pancreatic Insufficiency,
More news about: Columbus Marathon
Dec 31, 2025, 02:00 ET The Uygur ethnic group: Atlas silk exhibits enduring glamour of cultural diversity, unity
characterized primarily by designing the pattern before weaving. The threads are dyed first, then woven into fabric.Its origin inherently embodies a gene of "integration."Over one thousand years ago, sericulture and silk reeling techniques from the Central Plains were introduced to the Western
More news about: China.org.cn
Dec 30, 2025, 16:00 ET AMERICA'S TIRE AMPLÍA SU PRESENCIA MINORISTA EN NUEVA JERSEY
están oficialmente abiertas, por lo que invitamos a todo el condado de Burlington a venir a saludar y revisar sus neumáticos de forma gratuita", dijo Gene Bailey, gerente de la tienda America's Tire. "America's Tire puede ser una marca desconocida para los conductores de Nueva Jersey, pero nuestro equipo
More news about: Discount Tire
Dec 30, 2025, 14:59 ET AMERICA'S TIRE EXPANDS RETAIL FOOTPRINT INTO NEW JERSEY
are officially open, so we invite all of Burlington County to come say hello and get their tires checked for free," said America's Tire store manager Gene Bailey. "America's Tire might be an unfamiliar brand to the drivers of New Jersey, but our team of tire experts is ready and trained to provide the
More news about: Discount Tire
Dec 29, 2025, 21:40 ET QURE Investigation Notice: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm
On November 3, 2025, uniQure issued a press release revealing that the FDA notified the company that data for its AMT-130, an investigational gene therapy for Huntington's disease, did not provide sufficient evidence to support uniQure's Biologics License Application ("BLA") submission. Specifically,
More news about: Kessler Topaz Meltzer & Check, LLP
Dec 29, 2025, 06:40 ET Cell and Gene Therapy Market to Exceed US$105B by 2033, Driving Strategic Value Across Healthcare Portfolios | According to DataM Intelligence
Cell and Gene Therapy Market Intelligence: https://www.datamintelligence.com/download-sample/cell-and-gene-therapy-market Market OverviewCell and gene therapies
More news about: DataM Intelligence 4 Market Research LLP
Dec 29, 2025, 02:49 ET Diamyd Medical accelerates primary efficacy readout by 9 months in type 1 diabetes Phase 3 trial following FDA alignment and guidance
antigen-specific immunomodulatory therapeutic for the preservation of endogenous insulin production specifically for individuals carrying an HLA DR3-DQ2 gene. Diamyd® has been granted Orphan Drug Designation in the U.S. as well as Fast Track Designation by the U.S. FDA for the treatment of Stage
More news about: Diamyd Medical AB
Dec 29, 2025, 02:45 ET Diamyd Medical accelerates primary efficacy readout by 9 months in type 1 diabetes Phase 3 trial following FDA alignment and guidance
antigen-specific immunomodulatory therapeutic for the preservation of endogenous insulin production specifically for individuals carrying an HLA DR3-DQ2 gene. Diamyd® has been granted Orphan Drug Designation in the U.S. as well as Fast Track Designation by the U.S. FDA for the treatment of Stage
More news about: Diamyd Medical AB